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Abstract : The BiVACOR is a novel rotary Bi-Ventricular Assist Device (BiVAD) 
undergoing development to treat global end stage heart failure. The design includes left and 
right vanes positioned on a shared rotating hub to form a double-sided magnetically and 
hydro-dynamically suspended centrifugal impeller.   
The performance of the device was assessed in a pulsatile mock circulation loop replicating 
end stage bi-ventricular heart failure, and was shown to restore flow from pathological 
(2L/min) to normal levels (5L/min).  A novel technique to balance the left/right outflow of 
the BiVAD was also investigated, for which a maximum relative left to right outflow 
differential of 1.8L/min was achieved at normal physiologic afterloads.  
The in-vitro results encouraged device progression to in-vivo animal studies. Successful 
development of this BiVAD will provide a suitably miniature device for patients who require 
bi-ventricular assistance. 
Keywords : Rotary blood pump, Bi-Ventricular assist device, Heart failure 
(i) Introduction 
The use of mechanical device therapy to treat heart failure is increasing as the general 
population ages and the number of donor organs for heart transplantation remains limited (1).  
Left ventricular heart failure (LHF) is the most common affliction, for which a left 
ventricular assist device (LVAD) can provide sufficient circulatory support. However, a 
significant number of patients suffer from bi-ventricular heart failure (BHF), hence 
implantation of an additional right ventricular assist device (RVAD) is beneficial. The degree 
of bi-ventricular dysfunction is frequently underestimated in these patients, and right 
ventricular heart failure (RHF) may develop in up to 40% of patients receiving LVAD 
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assistance (2, 3). This condition  is associated with  mortality of  greater than 90 % when 
untreated (4, 5). Early introduction of an RVAD to complement the LVAD increases cardiac 
output and reduces central venous pressure (CVP), improving organ perfusion and potentially 
reversing the incipient multi-organ failure (MOF). 
Currently, two individually and extra-corporeally connected pulsatile type Thoratec™ 
devices (6) are used clinically to optimally treat bi-ventricular failure. These systems increase 
size, complexity, and therapy cost. Therefore, research at the Prince Charles Hospital (TPCH) 
is focused on developing a single rotary Bi-VAD that incorporates a method for balancing the 
left/right outflow and is suitably sized for implantation. 
The purpose of this paper is to detail the progressive design of the BiVACOR rotary Bi-VAD 
and present in-vitro results obtained from device operation within a mock circulation system.  
BiVAD Design 
The design of the BiVACOR device includes left and right vanes positioned on a shared 
rotating hub to form a magnetically and hydro-dynamically suspended centrifugal impeller. 
These respective vanes have a different outer diameter to produce the pressure required of the 
systemic and pulmonary systems at a common rotational speed. The instantaneous 
differential in flow required to balance outflow from the left and right hearts is achieved by 
alteration of axial clearance above each semi-open VAD impeller.  The suspension system 
under development incorporates an electromagnetic motor and bearing system for axial 
suspension and drive, while radial support is achieved using a hydrodynamic journal bearing. 
This journal bearing is well washed by the inherent shunt flow from left to right cavities.  
The relatively small size of the BiVACOR device enables intra-thoracic placement, utilizing 
inflow cannulation from the right atrium and left ventricle, and outflow cannulation to the 
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pulmonary artery and aorta. This strategy allows the intact native ventricles to provide an 
inflow reservoir and assist in balancing cardiac output. 
Error! Reference source not found. shows an exploded view detailing the anticipated 
placement of hydraulic and electromagnetic components, as well as the principle of flow 
differential production.  
(ii) Material and Methods 
To test the VAD hydraulic performance, a prototype was constructed which could centrally 
locate the impeller using a motor, shaft and sealed bearings to substitute initially for the 
magnetic/hydrodynamic bearing system. A micrometer mechanism attached to the motor and 
shaft assembly allowed precise, reproducible, and measureable axial displacement of the 
impeller within the pump cavity. This allowed simultaneous alteration of axial clearances 
above the left and right impeller vanes. The relative hydraulic performance with an axial 
movement of +/-0.3mm about the centralised position was then tested in a mock circulation 
loop filled with water at 20oC loop replicating a bi-ventricular heart failure (7).   
(iii) Results 
The desired haemodynamic condition of 5 L/min flow at 100mmHg and 20mmHg were 
attained at a set 2300rpm and 0.5mm axial clearance above each impeller (middle position). 
Alteration in performance of the LVAD and RVAD impellers for +/-0.3mm axial movement 
in a non-pulsatile system is detailed in Error! Reference source not found..  While 
maintaining arterial pressures, a 0.3mm movement toward the LVAD cavity flow increased 
left outflow to 6.4L/min while right outflow reduced to 4.6L/min, representing an 
instantaneous flow differential of 1.8L/min (36%).  
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Establishing the VAD into the circulation loop replicating BHF restored hemodynamics and 
resulted in the immediate alleviation of pulmonary and systemic congestion. Hemodynamic 
values for changes in arterial and atrial pressures as the impeller was moved from the right 
cavity toward the left cavity are displayed in Table 1. Paradoxically, RVAD outflow 
increased with motion to the LVAD cavity, due to an increase in hub washout leakage from 
left to right cavities.  
(iv) Discussion 
The current technique to treat BHF involves the implantation and operation of two separate 
pumps, which results in increased size and control complexity. The development of a safe, 
reliable, durable and suitably small, implantable single device BiVAD potentially removes 
many of the existing complications encountered whilst treating patients with global heart 
failure.  The single device creates the inability to remove RV support after implantation, 
however the device can operate successfully alongside a functioning right ventricle, and thus 
the device may remain in place should transient RV failure return. 
The double-sided impeller configuration of the BiVACOR reduces the potential for thrombus 
formation by eliminating areas of low flow or stagnation often found beneath single-sided 
centrifugal blood pump impellers. An electro- magnetic motor bearing is under development 
to suspend and drive the impeller, thus overcoming limitations of friction and wear at the 
drive shaft, seal and bearing interface. This would greatly increase the durability of the pump 
and reduce both heat generation and blood damage.  
Although similar to a ventricular septal defect, the shunt from the high pressure left to low 
pressure right cavity helps to wash the impeller. Leakage in this region is minimized to less 
than 20% by the incorporation of a radial hydrodynamic journal bearing.  
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The ability of a BiVAD to alter the left and right outflow is clinically ideal, in order to match 
bronchial flow (8, 9) which may increase with pulmonary disease (10), accommodate relative 
changes in systemic and pulmonary vascular resistance, account for relative levels of 
ventricular contractility, alleviate chronic pulmonic or systemic congestion, and to prevent 
ventricular collapse by acutely maintaining adequate atrial filling pressures.  
A previous attempt  to create a single device BiVAD/TAH could not actively provide 
variation in output flow from each cavity, since the impeller has a common rotational speed 
(11). The BiVACOR device addresses this limitation by using the magnetic suspension 
system to axially re-position the impeller within the pump cavity, which inversely alters the 
efficiency of each chamber. This technique effectively achieved left and right relative 
outflow alteration by up to 1.8L/min despite maintaining rotational speed at 2300rpm. The 
pump characteristic curves for the respective clearance gaps can be likened to those expected 
for a change in rotational speed of approximately 2200rpm-2500rpm.  
Analyzing the movement of impeller axial position in the simulated BHF environment 
(without baroreceptor reflex) not only showed an alteration of afterload pressure, but also 
preload atrial pressure. This represents a shift of fluid volume between the pulmonary and 
systemic circulations and can minimise the potential for the heart chambers to collapse.  
Due to the coupled nature of the LVAD and RVAD impellers, an inherent complication may 
arise when attempting to accommodate relative changes in SVR and PVR. One such clinical 
circumstance would arise if a heart failure patient presents with pulmonary hypertension. 
This hypertension is commonly secondary to elevated pulmonary arterial wedge pressures, 
which is reduced with left heart support. However, if it is a primary condition an elevated 
PVR compared to SVR may be present. This latter situation would limit the venous return to 
the LVAD side of the device, which may lead to left ventricular collapse. Agents such as 
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inhaled nitric oxide or prostacyclin may be used to reduce PHT whilst inducing no change in 
SVR –a technique commonly used in the critically ill patients with PHT who do not require 
mechanical support 
Since the impellers are coupled and there is a limit to the axial movement range in the device, 
a defined range of relative SVR and PVR can be accommodated. Potential difficulties may 
therefore arise in overcoming severe one sided hyper/hypotension in the current design, 
whereby fluid loading would be required to maintain sufficient left atrial pressure. Medical 
management of isolated pulmonary hypertension may be considered in these conditions. 
However, patients are routinely screened for pulmonary hypertension prior to heart 
transplant, which if severe, would preclude their eligibility for support.  
 (v) Conclusion 
The Bi-Ventricular assist device successfully restored hemodynamic perfusion from 
pathological to normal levels in a mock circulation loop replicating bi-ventricular heart 
failure.  The LVAD and RVAD impellers produced the desired hemodynamics of 5 L/min at 
100mmHg and 20mmHg respectively at a common rotational speed of 2300rpm and axial 
clearance of 0.5mm. The instantaneous imbalance of flow from the left and right hearts was 
achieved by simultaneously altering the axial clearance above each impeller, for which a 
maximum flow differential of 1.8L/min was observed. 
The in-vitro results encouraged device progression to in-vivo animal studies. Successful 
development of this device will provide a suitably miniature and relatively inexpensive 
device for patients who require bi-ventricular assistance. 
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Tables 
Table 1 – BHF support performance for axial clearance values at 2000rpm 
 Systemic Pulmonary 
Axial  
Position 
SQ 
(L/min) 
LAP 
(mmHg) 
MAP 
(mmHg) 
PQ 
(L/min) 
RAP 
(mmHg) 
MPAP 
(mmHg) 
+0.3mm 5.3 7.3 100 6.3 9.3 17.2 
0mm 5.1 9 93 5.7 8.2 17.8 
-0.3mm 4.9 11.8 86 5.5 6.3 19.3 
11 
Illustrations 
 
 
(a) RVAD movement (-0.3mm) (b) Middle Position (0mm) (c) LVAD movement (+0.3mm) 
Figure 1 – Exploded View of the BiVACOR showing the placement of magnetic and hydraulic components and 
conceptual illustration of impeller axial motion showing (a) LVAD leakage (b) LVAD to RVAD hub washout 
leakage and (c) RVAD leakage 
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Figure 2 – Individual LVAD (Upper) and RVAD (Lower) impeller performance curves for different axial positions 
at 2300rpm. Positive direction denotes movement toward the LVAD cavity from the centre. 
LEGEND 
LAP – Left Atrial Pressure,  
LVP – Left Ventricle Pressure,  
AoP – Aortic Pressure,  
MAP – Mean Arterial Pressure,  
RAP – Right Atrial Pressure,  
RVP – Right Ventricular Pressure,  
PAP – Pulmonary Arterial Pressure,  
MPAP – Mean Pulmonary Arterial Pressure,   
SQ – Systemic Flow Rate,  
MSQ – Mean Systemic Flow Rate,  
PQ – Pulmonary Flow Rate,  
MPQ – Mean Pulmonary Flow Rate 
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